Finanzen von Kalaris Therapeutics Inc (KLRS)KLRSKalaris Therapeutics Inc

Evaluating the bottom line, Kalaris Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -79.91%, provide a clear picture of how effectively KLRS converts its operational activities into shareholder value.

In the context of the broader market, KLRS competes directly with industry leaders such as OKYO and RLYB. With a market capitalization of $95.93M, it holds a leading position in the sector. When comparing efficiency, KLRS's gross margin of N/A stands against OKYO's N/A and RLYB's 100.00%. Such benchmarking helps identify whether Kalaris Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Kalaris Therapeutics has reported consistent net losses, with the latest net income at -11,515,000 USD for Q2 2026. The company has a negative EPS of -0.48 and a forward P/E ratio of 0, indicating challenges in profitability. However, the company is actively working on its lead candidate, TH103, which could change its financial outlook.